What It Does: Regeneron Pharmaceuticals is a biopharmaceutical company with marketed blockbuster drugs and advanced clinical pipelines. Dupixent (dupilumab), a monoclonal antibody for atopic dermatitis, eczema, and asthma, generated $14B+ in FY2024 revenue. Eylea (aflibercept), a monoclonal antibody for age-related macular degeneration (retinal disease), generated $9B+ in revenue. Regeneron is developing trevogrumab, an obesity program targeting GLP-1-resistant patients, with potential peak sales exceeding $10B. The company also has a diverse pipeline in inflammation, ophthalmology, and oncology. Regeneron generated $17B in FY2024 revenue, growing 33%+, with net income exceeding $3B. Operating margins exceed 45%.
How the Stock Looks: REGN trades near $750 with a market cap of $220 billion. The stock has appreciated ~65% in the past 18 months, supported by Dupixent and Eylea sales growth and obesity pipeline advancement. Operating margins expanded to 47% in FY2024, driven by blockbuster leverage. Free cash flow exceeds $5B annually. The valuation at 50x forward earnings is elevated but justified by blockbuster cash flows and obesity upside. Key catalysts include quarterly Dupixent and Eylea revenue trends, obesity pipeline Phase 3 trial results, competitive positioning relative to Novo Nordisk and Eli Lilly, and guidance updates.
What Analysts Are Saying: 32 analysts rate REGN a Buy, with consensus price target of $820. Bullish analysts from Goldman Sachs and Morgan Stanley highlight Dupixent's expanding indications (atopic disease mega-trend) and obesity program differentiation (targeting GLP-1-resistant populations). Eylea is a durable cash cow. Bears at JP Miller note obesity market competition and execution risk. However, analyst consensus is constructive: Dupixent is a multi-indication franchise, obesity represents upside optionality, and Eylea provides downside cash flow stability. The stock is a growth-at-reasonable-price biotech compounder.